UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 13, 2004
SCOLR Pharma, Inc.
| Delaware | 000-24693 | 91-1689591 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
3625 132nd Avenue SE
Suite 300
Bellevue, Washington 98006
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (425) 373-0171
| Item 12. Results of Operations and Financial Condition. | ||||||||
| SIGNATURES | ||||||||
| EXHIBIT INDEX | ||||||||
| EXHIBIT 99.1 | ||||||||
Item 12. Results of Operations and Financial Condition.
On August 13, 2004, SCOLR Pharma, Inc. issued a press release announcing its financial results for the fiscal quarter ended June 30, 2004. A copy of the press release is attached as Exhibit 99.1.
The information in this Current Report is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| SCOLR, INC. |
||||
| Dated: August 13, 2004 | By: | /s/ DANIEL O. WILDS | ||
| Daniel O. Wilds | ||||
| President and Chief Executive Officer | ||||
2